HIA
IBRX icon

HFM Investment Advisors’s ImmunityBio IBRX Stock Holding History

HFM Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246 Buy
+28
New +$212 ﹤0.01% 1155
2025
Q3 		– Sell
-4
Closed -$11 – 1290
2025
Q2 		$11 Sell
4
-2
-33% -$5 ﹤0.01% 1280
2025
Q1 		$19 Buy
+6
New +$18 ﹤0.01% 1159

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HFM Investment Advisors's IBRX Position: Q2 2026 in Review

HFM Investment Advisors opened a new position in ImmunityBio (IBRX) in Q2 2026: 28 shares worth $246. The stake represents ﹤0.01% of the portfolio and ranks #1155 among its holdings. This is a return to the name: HFM Investment Advisors previously reported a position in IBRX as recently as Q2 2025.

HFM Investment Advisors first reported a position in IBRX in Q1 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • HFM Investment Advisors held 28 shares of ImmunityBio worth $246 as of Q2 2026.
  • ImmunityBio was a new HFM Investment Advisors position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1155 holding.
  • HFM Investment Advisors first reported a position in ImmunityBio in Q1 2025 and has held it in 3 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.